Galena spins-out RXi, which gets $9.5mm in funding from investors
RXi Pharmaceuticals Corp. is splitting into two publicly traded companies: Galena Biopharma Inc. will focus on cancer therapeutics while the new RXi will spin off and continue the former company’s work on RNAi. In connection with the partial spin-off, two institutional investors purchased $9.5mm of RXi’s Series A preferred shares, an amount which includes shares converted from a $1.5mm bridge loan.
- Antisense, Oligonucleotides
- Large Molecule
- Convertible Debt
- Private Investment in Public Equity
- Private Placement
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com